NEW YORK, Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/o ...

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug ALTO-100, which failed to meet primary endpoints in clinical trials, leading to significant stock price decline [3][4][5]. Group 1: Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company focused on developing treatments for major depressive disorder (MDD) [3]. - The company conducted its initial public offering (IPO) on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Group 2: Allegations and Impact - The lawsuit claims that during the Class Period, Alto Neuroscience made false or misleading statements about the effectiveness of ALTO-100, overstating its clinical and commercial prospects [4]. - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - As of the filing of the class action, Alto Neuroscience's stock continues to trade below the IPO price of $16.00 per share [6].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against the Company - The complaint alleges that the effectiveness of Alto's product pipeline, specifically ALTO-100, in treating major depressive disorder was overstated [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were misrepresented, leading to an inflated perception of Alto's business and financial outlook [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and fraud, emphasizing the importance of responsible business practices [6].

Core Points - A lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) for alleged violations of securities laws related to its IPO and subsequent statements [3] - Investors who purchased over $100,000 in shares between February 2, 2024, and October 22, 2024, have a deadline of September 19, 2025, to take action [2] - The lawsuit claims that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated, leading to misleading public statements about the company's financial and business prospects [3] Company Information - Alto Neuroscience, Inc. is facing legal scrutiny due to allegations that its IPO documents contained false or misleading information regarding its product's effectiveness [3] - The Shareholders Foundation, Inc. is facilitating communication for affected investors and provides services related to shareholder issues and securities class actions [4]

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired: (a) Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, ...

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Allegations and Misleading Information - The Offering Documents related to the IPO were claimed to be negligently prepared, leading to misinformation about ALTO-100's effectiveness in treating major depressive disorder (MDD) [2]. - It was alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, which in turn inflated Alto's business and financial outlook [2]. Group 2: Clinical Trial Results and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial for MDD, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, representing a 69.99% decline, closing at $4.36 per share on October 23, 2024 [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the company's product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - The complaint against Alto alleges violations of federal securities laws due to misleading statements regarding the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) and the overstated prospects of the company's business and financial performance [2]. Group 1: Company Performance and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [3]. - Following the announcement, Jeffries reduced its price target for Alto from $33 to $17, indicating concerns about the company's biomarker approach to central nervous system disorders and psychiatry [4]. Group 2: Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [5]. - The law firm Faruqi & Faruqi encourages individuals with information regarding Alto's conduct to come forward, including whistleblowers and former employees [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and its effectiveness in treating major depressive disorder [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [6].